Cefovecin is an extended-spectrum cephalosporin that was recently approved for veterinary use. The drug has a long half-life (5.5 days) and therapeutic concentrations are maintained for approximately 14 days. The clinical efficacy of cefovecin was compared with amoxicillin-clavulanic acid oral tablets in 3 separate treatment protocols. Only dogs with naturally occurring untreated bacterial pyoderma (superficial, deep, and wound abscesses) were included in the studies. Dogs were randomly assigned to a treatment group and received either 8 mg/kg of cefovecin by SC injection at 14-day intervals (n = 242) or 10 mg/kg amoxicillin combined with 2.5 mg/kg clavulanic acid orally twice daily for 14 days (n = 112). Courses of treatment were repeated for 14-day intervals as needed for a maximum of 4 cycles or 56 days. Severity of lesions was scored at days 0, 7, and 14 and every 14 days thereafter, including 14 days after the end of therapy. Staphylococcus intermedius was the most commonly isolated pathogen (n = 223); however, other bacteria were isolated (Escherichia coli, Streptococcus, Enterobacter, Pasteurella multocida, Pseudomonas, Proteus, and Acinetobacter). Injection site reactions were noted in only 2 of 242 dogs receiving cefovecin. Diarrhea or soft stools, inappetence, and lethargy were similar between the 2 groups. Vomiting was observed in 3 of 242 and 12 of 112 dogs treated with cefovecin and amoxicillin-clavulanic acid, respectively. Cefovecin was demonstrated to be statistically noninferior when compared with amoxicillin-clavulanic acid. Study funded by Pfizer, Ltd

COMMENTARY: Development of long-acting injectable antibiotics for treatment of canine pyoderma is one of the few "new" treatments to date. In this study, cefovecin had a wide spectrum of activity, was well tolerated, and was similar to amoxicillin-clavulanic acid in the treatment of superficial and deep pyoderma and wounds. Testing this drug in cats would be particularly useful because they are especially difficult for clients to medicate. This drug will facilitate treatment of pyoderma not only because of improved compliance but also because it will potentially increase monitoring-dogs will need to return for at least 1 and possibly 4 injections after diagnosis, which translates into 2 to 3 follow-up appointments. Testing in larger populations of dogs will further elucidate this drug's usefulness. This drug is not yet available in the United States.

Clinical efficacy and safety of cefovecin in the treatment of canine pyoderma and wound infections. Stegemann MR, Coati N, Passmore CA, Sherington J. J Small Anim Pract 48:378-386, 2007.